Login / Signup

Anti-Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome.

Wanwarang WongcharoenNualnit TantisirivitLalita NorasetthadaSiriluck GunaparnArintaya Phrommintikul
Published in: The Annals of pharmacotherapy (2020)
Anti-FXa activity of the second dose of fondaparinux was higher in low-BW patients but still within the expected range.
Keyphrases
  • body weight
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes